ALEXANDRIA, Va. – The country’s leading pharmacy groups said that any action on a prescription drug rebate rule must address skyrocketing fees extracted by pharmacy benefit managers on behalf of plan sponsors in Medicare Part D.
“We remind the Administration of the continuous and heightened impact of pharmacy DIR fees imposed by Medicare Part D plan sponsors and their pharmacy benefit managers (PBMs) on our members. Pharmacy DIR fees are growing beyond CMS’ projection of 10% year-over-year. This growth of pharmacy DIR fees is especially unsustainable during the current COVID-19 PHE when our members, representing every aspect of the pharmacy industry, care for patients, while also providing desperately needed access to COVID-19 tests and related services,”said the groups in a letter to HHS Secretary Alex Azar this week.
The groups include: the National Community Pharmacists Association; the American Pharmacists Association; the National Association of Chain Drug Stores; the National Association of Specialty Pharmacy; FMI-The Food Industry Association; and the National Grocers Association.
Print Page
Email to a Friend